Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome

Part of paid clinical trials in Lexington, Kentucky.

Sponsor
Retina Associates of Kentucky
Study ID
NCT00955630
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

  • Ocular Histoplasmosis Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • ranibizumab — DRUG
    3 monthly injections of ranibizumab followed by prn injections for the remainder of the study
  • ranibizumab — DRUG
    prn injections of ranibizumab throughout the study

Study Details

The purpose of this study is to evaluate the safety and effectiveness of intravitreal ranibizumab (Lucentis) in patients with fluid and blood leakage in their eyes due to ocular histoplasmosis.

Key Dates

First listed
Aug 10, 2009
Start date
Aug 31, 2009
Status verified
Aug 2009
Primary completion
Aug 31, 2010

Study Design

Enrollment
20 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Active Comparator: Monthly injections
    3 monthly injections of ranibizumab followed by prn injections
  • Active Comparator: PRN injections
    injections of ranibizumab on a prn basis from the start of the study

Primary Outcome Measure

incidence and severity of ocular adverse events as identified by eye examination [ Time Frame: 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Retina Associates of KentuckyLexingtonKentucky40509
John Kitchens, MD (PRINCIPAL_INVESTIGATOR)
Tom Stone, MD (SUB_INVESTIGATOR)
William J Wood, MD (SUB_INVESTIGATOR)
Rick D Isernhagen, MD (SUB_INVESTIGATOR)

Find similar trials in Lexington, KY

By research site
Retina Associates of Kentucky· Lexington, KY